2024
Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccine
2022
Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study
Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, Thornhill T, Gonsalves G. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open 2022, 12: e061752. PMID: 36100306, PMCID: PMC9471205, DOI: 10.1136/bmjopen-2022-061752.Peer-Reviewed Original ResearchConceptsLow-income countriesIncome countriesDeath avertedHigh-income nationsStatistical lifeAvertable deathsIncome nationsCOVID-19 deathsReasonable investmentHigh costKey inputCountriesParameter estimatesAvertedCostSensitivity analysisUniversal vaccinationGlobal vaccinationMRNA COVID-19 vaccinationNationsInvestmentPrimary vaccine seriesLow vaccine effectivenessCOVID-19 vaccinationPublic data
2020
Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy
Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. Health Affairs 2020, 40: 42-52. PMID: 33211536, PMCID: PMC7931245, DOI: 10.1377/hlthaff.2020.02054.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineVaccine efficacyCoronavirus disease 2019 (COVID-19) vaccinesSignificant vaccine hesitancyClinical outcomesClinical trialsVaccination programVaccine hesitancyEpidemic severityVaccineAuthorized vaccinesHealth officialsCumulative infectionsEfficacyVaccine productionDistribution programSeverityOutcomesUrgent needHospitalizationVaccinationInfectionTrialsGlobal efforts
2019
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The Lancet Infectious Diseases 2019, 19: 728-739. PMID: 31130329, PMCID: PMC6595249, DOI: 10.1016/s1473-3099(18)30804-1.Peer-Reviewed Original ResearchConceptsGross domestic productWTP valuesCountry's gross domestic productOptimal strategyCountry-specific willingnessAverage net benefitHealth economic evaluationsGAVI-eligible countriesTyphoid ViPay valueDomestic productVaccine priceWTP thresholdEconomic evaluationVaccine-related costsNet benefitMiddle-income countriesGavi supportVaccine AllianceRoutine immunisationHospital admissionCountriesTCV introductionDALYsTransmission dynamic model
2016
Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa
Bilinski AM, Fitzpatrick MC, Rupprecht CE, Paltiel AD, Galvani AP. Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. Proceedings Of The Royal Society B 2016, 283: 20161211. PMID: 27852799, PMCID: PMC5124087, DOI: 10.1098/rspb.2016.1211.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDog DiseasesDogsHumansImmunization ProgramsRabiesRabies VaccinesRabies virusTanzaniaVaccinationConceptsVaccination campaignRabies vaccination campaignsOptimal vaccination strategyPublic health benefitsWorld Health OrganizationVaccination strategiesRabies vaccinationVirus transmission modelDisease reintroductionSub-Saharan AfricaHealth OrganizationHealth benefitsRabies reintroductionRabiesNorthwest TanzaniaHuman deathsPrevious studiesVaccinationYearsDisease
2014
Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania.
Fitzpatrick MC, Hampson K, Cleaveland S, Mzimbiri I, Lankester F, Lembo T, Meyers LA, Paltiel AD, Galvani AP. Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania. Annals Of Internal Medicine 2014, 160: 91-100. PMID: 24592494, PMCID: PMC4084874, DOI: 10.7326/m13-0542.Peer-Reviewed Original ResearchConceptsVaccination campaignCanine vaccinationPrompt postexposure prophylaxisBase-case analysisVaccination coverageHuman rabiesSocietal willingnessProbability-based evaluationU.S. dollarsEconomic outcomesContact-tracing studiesEmpirical uncertaintyRural AfricaRural TanzaniaOptimal vaccination coverageOngoing vaccination campaignRabies vaccination campaignsGreat uncertaintyAnnual mortality ratePostexposure prophylaxisEpidemiologic variablesTransmission of rabiesHealth burdenWillingnessMortality rate
2013
Dengue dynamics and vaccine cost-effectiveness in Brazil
Durham DP, Mbah M, Medlock J, Luz PM, Meyers LA, Paltiel AD, Galvani AP. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 2013, 31: 3957-3961. PMID: 23791696, PMCID: PMC3755607, DOI: 10.1016/j.vaccine.2013.06.036.Peer-Reviewed Original ResearchConceptsVaccination costsDengue vaccine trialsVaccine efficacyTotal vaccination costDengue vaccinationCost-effectiveness analysisPotential vaccination policiesVaccine trialsPay thresholdsVaccine efficacy scenariosOptimal allocationLow vaccine efficacyLatest clinical trialsOptimistic scenarioTrial estimatesVaccination coverageEfficacy scenariosClinical trialsAvailable dosesVaccination policyFurther trialsVaccination modelHerd immunityVaccinationCost
2012
Impact of Program Scale and Indirect Effects on the Cost-Effectiveness of Vaccination Programs
Ibuka Y, Paltiel AD, Galvani AP. Impact of Program Scale and Indirect Effects on the Cost-Effectiveness of Vaccination Programs. Medical Decision Making 2012, 32: 442-446. PMID: 22472916, PMCID: PMC3570235, DOI: 10.1177/0272989x12441397.Peer-Reviewed Original Research